License agreement for development and sale of Teribone™ in Korea

December 3, 2014
Asahi Kasei Pharma Corp.

Asahi Kasei Pharma has concluded a license agreement with Dong-A ST Co., Ltd. (Dong-A ST) granting Dong-A ST exclusive rights in Korea for the development and sale of Teribone™ osteoporosis drug (generic name: teriparatide acetate; product name in Japan: Teribone™ 56.5 µg subcutaneous injection). Dong-A ST will now advance development in preparation for an application for approval in Korea.

Teribone™ is a human parathyroid hormone that facilitates bone formation. With weekly subcutaneous injections, Teribone™ decreases the risk of bone fracture. The efficacy in inhibiting fracture is obtained by increasing bone strength with both improved bone quality and increased bone density.

In Korea, it is predicted that the number of people suffering from osteoporosis will continue to increase as the population ages. Since osteoporosis carries an increased risk of vertebral and femoral fracture, with a high probability of resulting in confinement to bed, the implementation of effective measures against osteoporosis is an important social issue. Through its partnership with Dong-A ST, Asahi Kasei Pharma believes that Teribone™ will make a significant contribution to the treatment of osteoporosis in Korea.

This is Asahi Kasei Pharma’s second collaboration with Dong-A ST, following a similar license agreement in 2009 for Flivas™ (naftopidil). The license agreement for Teribone™ further reinforces the cooperative relationship between the companies.

Corporate profile of Dong-A ST Co., Ltd.

President:   Park Chan-il
Head office:   Seoul, Korea
Paid-in capital:   38.5 billion won
Business line:   Manufacture and sale of pharmaceuticals
Net sales:   495.8 billion won (March–December 2013)*
Employees:   1,556 (as of June 30, 2014)

* Dong-A ST was established in March 2013 through a corporate reorganization.


Adobe Readeris required to view these PDF files.

page top